心脏术后心源性休克的严重程度分级

doi:10.3969/j.issn.1006-7795.2024.02.026

摘要/Abstract

摘要： 心脏术后心源性休克严重程度的分级对于制定合理的治疗方案和预测预后具有重要意义。本文旨在探讨心脏术后心源性休克的定义、病因、病理生理以及一般管理，对传统血流动力学分型与休克管理进行综述，并讨论严重程度分级与休克管理的研究现状。

关键词: 心脏手术, 休克管理, 围术期, 心源性休克

Abstract: The severity classification of post-cardiotomy cardiogenic shock is important for developing a rational treatment plan and predicting prognosis. The aim of this article is to explore the definition, etiology, pathophysiology, and general management of post-cardiotomy cardiogenic shock, to provide a review of traditional hemodynamic classification and shock management, and to discuss the current state of research on severity classification and shock management.

Key words: cardiotomy, shock management, perioperative period, cardiogenic shock

中图分类号:

王奕文, 李呈龙, 侯晓彤. 心脏术后心源性休克的严重程度分级[J]. 首都医科大学学报, 2024, 45(2): 363-370.

Wang Yiwen, Li Chenglong, Hou Xiaotong. Severity classification of post-cardiotomy cardiogenic shock[J]. Journal of Capital Medical University, 2024, 45(2): 363-370.

参考文献

［1］ Wolk M J, Bailey S R, Doherty J U, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons ［J］. J Am Coll Cardiol, 2014, 63(4): 380-406.
［2］ Jentzer J C, Baran D A, van Diepen S, et al. Admission society for cardiovascular angiography and intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients［J］. Am Heart J, 2020, 219: 37-46.
［3］ Schrage B, Dabboura S, Yan I, et al. Application of the SCAI classification in a cohort of patients with cardiogenic shock［J］. Catheter Cardio Inte, 2020, 96(3): E213-E219.
［4］ Samsky M D, Morrow D A, Proudfoot A G, et al. Cardiogenic shock after acute myocardial infarction: a review［J］. JAMA, 2021, 326(18): 1840-1850.
［5］ Diepen S V, Katz J N, Albert N M, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association［J］. Circulation, 2017, 136(16): e232-e268.
［6］ Aissaoui N, Puymirat E, Tabone X, et al. Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French Nationwide Registries［J］. Eur Heart J, 2012, 33(20): 2535-2543.
［7］ Jentzer J C, Schrage B, Holmes D R, et al. Influence of age and shock severity on short-term survival in patients with cardiogenic shock［J］. Eur Heart J Acute Cardiovasc Care, 2021, 10(6): 604-612.
［8］ Jentzer J C, van Diepen S, Barsness G W, et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit［J］. J Am Coll Cardiol, 2019, 74(17): 2117-2128.
［9］ Thayer K L, Zweck E, Ayouty M, et al. Invasive hemodynamic assessment and classification of in-hospital mortality risk among patients with cardiogenic shock［J］. Circ Heart Fail, 2020, 13(9): e007099.
［10］ Baran D A, Long A, Badiye A P, et al. Prospective validation of the SCAI shock classification: single center analysis［J］. Catheter Cardiovasc Interv, 2020, 96(7): 1339-1347.
［11］ Hill K L, Rustin M A, Asche M A, et al. Cardiogenic shock classification and associated mortality risk［J］. Mayo Clin Proc, 2023, 98(5): 771-783.
［12］李浪. 2019 SCAI心原性休克分类临床专家共识声明解读［J］. 中国循环杂志, 2019, 34(S1): 98-100.
［13］ Cherbi M, Bouisset F, Bonnefoy E, et al. Characteristics, management, and mid-term prognosis of older adults with cardiogenic shock admitted to intensive care units: insights from the FRENSHOCK registry［J］. Int J Cardiol, 2024, 395: 131578.
［14］ Fukano K, Iizuka Y, Nishiyama S, et al. Characteristics of pulmonary artery catheter use in multicenter ICUs in Japan and the association with mortality: a multicenter cohort study using the Japanese intensive care PAtient database［J］. Crit Care (Fullerton), 2023, 27(1): 412.
［15］ Hajjar L A, Vincent J L, Barbosa Gomes Galas F R, et al.Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: The VANCS Randomized Controlled Trial［J］.Anesthesiology,2017,126(1):85-93.
［16］ Dumont R, Tridetti J, Ancion A, et al. Cardiogenic shock: etiology and management［J］.Rev Med liege, 2021, 76(2): 88-92.
［17］杨焱淼, 罗刚, 王峰, 等. 成人心脏瓣膜病术后肺部感染与体外循环时间及手术时间相关性分析［J］. 现代医药卫生, 2018, 34(18): 2895-2896, 2908.
［18］ Danial P, Olivier M E, Bréchot N, et al. Association between shock etiology and 5-year outcomes after venoarterial extracorporeal membrane oxygenation［J］. J Am Coll Cardiol, 2023, 81(9): 897-909.
［19］ Sag C M, Zeymer U, Ouarrak T, et al.Effects of on-hours versus off-hours admission on outcome in patients with myocardial infarction and cardiogenic shock: results from the CULPRIT-SHOCK Trial［J］.Circ Cardiovasc Interv,2020,13(9):e009562.
［20］ Huisman M V, Barco S, Cannegieter S C, et al. Pulmonary embolism［J］. Nat Rev Dis Primers, 2018, 4: 18028.
［21］ Balik M, Maly M, Brozek T, et al. Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial［J］. Intensive Care Med, 2023, 49(11): 1283-1292.
［22］ Xiao F P, Chen M Y, Wang L, et al. Outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review and meta-analysis of 225,841 patients［J］. Am J Emerg Med, 2021, 42: 23-30.
［23］ Vakamudi S, Ho N, Cremer P C. Pericardial effusions: causes, diagnosis, and management［J］. Prog Cardiovasc Dis, 2017, 59(4): 380-388.
［24］ Senapati A, Faza N N, Mahmarian J, et al. Cardiac computed tomography for structural heart disease assessment and therapeutic planning: focus on prosthetic valve dysfunction［J］. Methodist Debakey Cardiovasc J, 2020, 16(2): 86-96.
［25］ Kohsaka S, Menon V, Lowe A M, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock［J］. Arch Intern Med, 2005, 165(14): 1643-1650.
［26］ Fallick C, Sobotka P A, Dunlap M E. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation［J］. Circ Heart Fail, 2011, 4(5): 669-675.
［27］ Konstam M A, Kiernan M S, Bernstein D, et al. Evaluation and management of Right-Sided heart failure: a scientific statement from the American Heart Association［J］. Circulation, 2018, 137(20): e578-e622.
［28］ Jentzer J C, Pöss J, Schaubroeck H, et al. Advances in the management of cardiogenic shock［J］. Crit Care Med, 2023, 51(9): 1222-1233.
［29］ Menon V, White H, LeJemtel T, et al. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries in cardiogenic shocK?［J］. J Am Coll Cardiol, 2000, 36(3 Suppl A): 1071-1076.
［30］ Roeschl T, Hinrichs N, Hommel M, et al. Systematic assessment of shock severity in postoperative cardiac surgery patients［J］. J Am Coll Cardiol, 2023, 82(17): 1691-1706.
［31］ Klein L W, Shaw R E, Krone R J, et al. Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model［J］. Am J Cardiol, 2005, 96(1): 35-41.
［32］ Alba A C, Foroutan F, Buchan T A, et al. Mortality in patients with cardiogenic shock supported with VA ECMO: a systematic review and meta-analysis evaluating the impact of etiology on 29,289 patients［J］. J Heart Lung Transpl, 2021, 40(4): 260-268.
［33］ Hanson I D, Tagami T, Mando R, et al. SCAI shock classification in acute myocardial infarction: insights from the National Cardiogenic Shock Initiative［J］. Catheter Cardiovasc Interv, 2020, 96(6): 1137-1142.
［34］ Szerlip M, Feldman D N, Aronow H D, et al. SCAI publications committee manual of standard operating procedures［J］. Catheter Cardio Inte, 2020, 96(1): 145-155.
［35］ Jentzer J C, Ahmed A M, Vallabhajosyula S, et al. Shock in the cardiac intensive care unit: changes in epidemiology and prognosis over time［J］. Am Heart J, 2021, 232: 94-104.
［36］ Pöss J, Desch S, Thiele H. Shock management in acute myocardial infarction［J］. EuroIntervention, 2014, 10(Suppl T): T74-T82.
［37］ Nguyen H L, Lessard D, Spencer F A, et al. Thirty-year trends (1975-2005) in the magnitude and hospital death rates associated with complete heart block in patients with acute myocardial infarction: a population-based perspective［J］. Am Heart J, 2008, 156(2): 227-233.
［38］ Levy B, Buzon J, Kimmoun A.Inotropes and vasopressors use in cardiogenic shock: when, which and how much?［J］.Curr Opin Crit Care,2019,25(4):384-390.
［39］ Mathew R, Di Santo P, Jung R G, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock［J］. N Engl J Med, 2021, 385(6): 516-525.
［40］曹烨, 王磊, 王书鹏, 等. 冠状动脉旁路移植术后主动脉内球囊反搏应用的危险因素分析及预测模型的构建［J］. 心肺血管病杂志, 2023, 42(12): 1243-1250.
［41］ Uil C A D, Van Mieghem N M, B Bastos M, et al. Primary intra-aortic balloon support versus inotropes for decompensated heart failure and low output: a randomised trial［J］. EuroIntervention, 2019, 15(7): 586-593.
［42］ Ostadal P, Rokyta R, Karasek J, et al. Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: results of the ECMO-CS randomized clinical trial［J］. Circulation, 2023, 147(6): 454-464.
［43］ Pöss J, Köster J, Fuernau G, et al. Risk stratification for patients in cardiogenic shock after acute myocardial infarction［J］. J Am Coll Cardiol, 2017, 69(15): 1913-1920.
［44］ Jentzer J C, Baran D A, Kyle Bohman J, et al. Cardiogenic shock severity and mortality in patients receiving venoarterial extracorporeal membrane oxygenator support［J］. Eur Heart J Acute Cardiovasc Care, 2022, 11(12): 891-903.
［45］ Baran D A, Grines C L, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019［J］. Catheter Cardiovasc Interv, 2019, 94(1): 29-37.
［46］ Wiley B M, Eckman P M, Jentzer J C. Vasopressor load: sounding the alarm in management of cardiogenic shock associated with acute myocardial infarction［J］. Crit Care Med, 2021, 49(5): 865-869.
［47］ Hyun J, Kim A R, Lee S E, et al. Vasoactive-Inotropic score as a determinant of timely initiation of venoarterial extracorporeal membrane oxygenation in patients with cardiogenic shock［J］. Circ J, 2022, 86(4): 687-694.
［48］ Zahn R, Hamm C W, Schneider S, et al. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry［J］. Am Heart J, 2006, 152(6): 1146-1152.
［49］ Lawler P R, Berg D D, Park J G, et al. The range of cardiogenic shock survival by clinical stage: data from the critical care cardiology trials network registry［J］. Crit Care Med, 2021, 49(8): 1293-1302.
［50］ Sleeper L A, Reynolds H R, White H D, et al. A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK Trial and Registry［J］. Am Heart J, 2010, 160(3): 443-450.
［51］ Naidu S S, Baran D A, Jentzer J C, et al. SCAI SHOCK stage classification expert consensus update: a review and incorporation of validation studies: this statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021［J］. J Am Coll Cardiol, 2022, 79(9): 933-946.
［52］ Shih H H, Kang P L, Pan J Y, et al. Performance of European system for cardiac operative risk evaluation in Veterans General Hospital Kaohsiung cardiac surgery［J］. J Chin Med Assoc, 2011, 74(3): 115-120.
［53］ Han S, Chu H, Liang Y. Measurement of blood pressure for sedated colonoscopy. Comment on Br J Anaesth, 2022, 128:610-622［J］. Br J Anaesth, 2022, 129(2): E25.

[1]	庹琳, 包小源. 蛛网膜下腔出血院内病死率的预测模型[J]. 首都医科大学学报, 2024, 45(2): 348-355.
[2]	李丽娜, 杨敏福. 心血管成纤维细胞显像的现状和展望[J]. 首都医科大学学报, 2024, 45(1): 46-51.
[3]	马薇, 周一帆, 姜慧敏, 卫慧敏, 周陈, 吉训明. 脑静脉窦血栓形成动物模型研究进展[J]. 首都医科大学学报, 2023, 44(5): 704-714.
[4]	冯丹, 李娜, 侯东燕. 血清残粒脂蛋白胆固醇浓度与急性心肌梗死相关性分析[J]. 首都医科大学学报, 2023, 44(5): 872-876.
[5]	何莎, 苑梦伟, 高雁, 苟东芸, 李漾, 邱会卿. 河北汉族ApoE基因多态性与心脑血管疾病的相关性[J]. 首都医科大学学报, 2023, 44(5): 852-858.
[6]	周力, 朱超, 王福财, 崔贺贺, 刘青波, 赵慧强, 陈晖. 药物涂层球囊在急性心肌梗死直接经皮冠状动脉介入术中的应用[J]. 首都医科大学学报, 2023, 44(4): 669-675.
[7]	高霞, 延晋, 姚志, 王广. 三酰甘油葡萄糖指数与新诊断的冠状动脉粥样硬化性心脏病患者冠状动脉病变程度的相关性[J]. 首都医科大学学报, 2023, 44(3): 381-386.
[8]	韦莹, 王广. 糖化血红蛋白指数升高增加颈动脉斑块风险[J]. 首都医科大学学报, 2023, 44(3): 387-392.
[9]	李杰, 张隽, 王晶, 华琳, 张黎明. 嗜酸性肉芽肿性多血管炎肾受累的临床分析[J]. 首都医科大学学报, 2023, 44(3): 494-500.
[10]	罗晓萌, 江雪, 杜凤和, 郭彩霞. 急性冠状动脉综合征患者血浆sRAGE、IFN-γ浓度及其与冠状动脉病变严重程度的关系[J]. 首都医科大学学报, 2023, 44(2): 272-279.
[11]	徐建可, 刘宁, 韩苗, 张洪阳, 韩新生. 缺血性脑卒中患者颈动脉斑块性质与非高密度脂蛋白胆固醇浓度的相关性[J]. 首都医科大学学报, 2023, 44(1): 49-53.
[12]	王荣荣, 田俊萍. 急性冠脉综合征患者血清钙与心血管预后的关系[J]. 首都医科大学学报, 2023, 44(1): 154-160.
[13]	赵继宗. 我国脑心血管共患疾病现状与临床研究[J]. 首都医科大学学报, 2022, 43(5): 671-673.
[14]	冯莉, 杨佳雪, 李新, 贾长琪, 蒋晨曦. hERG1a突变H70R对hERG1a单源四聚体和hERG1a/hERG1b二源四聚体通道功能的影响[J]. 首都医科大学学报, 2022, 43(5): 747-753.
[15]	马艺欣, 张仲迎, 佀思聪, 罗鸿宇, 赵欢, 杨伟. 2型糖尿病患者新型脂肪因子血清内脏脂肪素和内脏脂肪特异性丝氨酸蛋白酶抑制因子的表达水平与左心室肥厚的关系[J]. 首都医科大学学报, 2022, 43(5): 767-773.